1. Home
  2. SCNX vs QTTB Comparison

SCNX vs QTTB Comparison

Compare SCNX & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCNX
  • QTTB
  • Stock Information
  • Founded
  • SCNX 2010
  • QTTB 2015
  • Country
  • SCNX United States
  • QTTB United States
  • Employees
  • SCNX N/A
  • QTTB N/A
  • Industry
  • SCNX Other Pharmaceuticals
  • QTTB Biotechnology: Pharmaceutical Preparations
  • Sector
  • SCNX Health Care
  • QTTB Health Care
  • Exchange
  • SCNX Nasdaq
  • QTTB Nasdaq
  • Market Cap
  • SCNX 21.2M
  • QTTB 18.9M
  • IPO Year
  • SCNX 2020
  • QTTB N/A
  • Fundamental
  • Price
  • SCNX $1.21
  • QTTB $1.97
  • Analyst Decision
  • SCNX
  • QTTB Hold
  • Analyst Count
  • SCNX 0
  • QTTB 8
  • Target Price
  • SCNX N/A
  • QTTB $24.00
  • AVG Volume (30 Days)
  • SCNX 330.0K
  • QTTB 227.4K
  • Earning Date
  • SCNX 08-12-2025
  • QTTB 08-06-2025
  • Dividend Yield
  • SCNX N/A
  • QTTB N/A
  • EPS Growth
  • SCNX N/A
  • QTTB N/A
  • EPS
  • SCNX N/A
  • QTTB N/A
  • Revenue
  • SCNX $128,202.00
  • QTTB N/A
  • Revenue This Year
  • SCNX N/A
  • QTTB N/A
  • Revenue Next Year
  • SCNX N/A
  • QTTB N/A
  • P/E Ratio
  • SCNX N/A
  • QTTB N/A
  • Revenue Growth
  • SCNX N/A
  • QTTB N/A
  • 52 Week Low
  • SCNX $0.69
  • QTTB $1.35
  • 52 Week High
  • SCNX $10.23
  • QTTB $53.79
  • Technical
  • Relative Strength Index (RSI)
  • SCNX N/A
  • QTTB 50.74
  • Support Level
  • SCNX N/A
  • QTTB $1.57
  • Resistance Level
  • SCNX N/A
  • QTTB $2.08
  • Average True Range (ATR)
  • SCNX 0.00
  • QTTB 0.22
  • MACD
  • SCNX 0.00
  • QTTB -0.03
  • Stochastic Oscillator
  • SCNX 0.00
  • QTTB 53.04

About SCNX Scienture Holdings Inc. Common Stock

Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.

About QTTB Q32 Bio Inc. Common Stock

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Share on Social Networks: